Navigation Links
Christopher Brennan Joins PharmaNet Development Group as General Counsel
Date:9/22/2009

PRINCETON, N.J., Sept. 22 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Christopher S. Brennan has joined the Company as general counsel.

"We are very pleased to have Chris join the PharmaNet Development Group management team," commented Jeffrey P. McMullen, president and chief executive officer. "His diversified experience and expertise will bring valuable insight to the Company and support our growth strategies."

Previously, Mr. Brennan held the position of general counsel at a specialty pharmaceutical company and worked in private practice as a corporate transactional attorney at two prominent, multi-national law firms -- Cravath, Swaine & Moore LLP and Dechert LLP. While at these two global law firms, Mr. Brennan worked along side management teams from various Fortune 500 companies while helping them to successfully undertake and complete company "mission critical" transactions in the areas of mergers and acquisitions, corporate financing, joint ventures, licensing, corporate partnering, private financing and public securities -- all primarily in the pharmaceutical and emerging life science market place.

Mr. Brennan graduated from Fordham University School of Law with honors. For the five years prior to entering law school, he managed multi-million dollar, high-technology projects and led large project teams from various disciplines as a Captain in the United States Air Force.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842
    E-mail: ahess@pharmanet.com


'/>"/>
SOURCE PharmaNet Development Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
2. Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants
3. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
4. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
7. Christopher and Dana Reeve Foundation Response to FDA Clearance of Gerons Clinical Trial
8. VITAS Innovative Hospice Care(R) Names Christopher Rieder Senior Vice President and Chief Information Officer
9. Fina Technologies Names Spotfire Founder Christopher Ahlberg to Board of Directors
10. DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice
11. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... SAN DIEGO, Dec. 8, 2016  OncoSec Medical ... company developing DNA-based intratumoral cancer immunotherapies, today announced ... "We are delivering on our ... melanoma with ImmunoPulse® IL-12. We are pleased with ... melanoma combination trial, and we are focused on ...
(Date:12/8/2016)... , December 8, 2016 AskLinkerReports.com ... comprehensive analysis, titled Global Amyloglucosidase Industry 2016 Market Research Report. ... application, and industry chain overview are all covered in the ... analysis, and investment return analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)...  Renova™ Therapeutics, a biotechnology company developing gene ... 2 diabetes, announced that it has obtained a ... vector developed in the laboratory of Professor ... The company plans to use this vector in ... "Early research has shown promise ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... light to control cells — optogenetics — is key to exciting advances in ... the art, spatially patterned light projected via free-space optics stimulates small, transparent organisms ...
Breaking Biology Technology:
(Date:11/30/2016)... 30, 2016 Not many of us realize that we spend ? of ... we need to do it well. Inadequate sleep levels have been found to lead ... diabetes, and even cancer. Maybe now is the best time to rethink ... them to manage their sleep quality? Continue Reading ... ...
(Date:11/28/2016)... Nov. 28, 2016 "The ... of 16.79%" The biometric system market is in ... in the near future. The biometric system market is ... 2022, at a CAGR of 16.79% between 2016 and ... of biometric technology in smartphones, rising use of biometric ...
(Date:11/19/2016)... 2016 Securus Technologies, a leading provider of ... investigation, corrections and monitoring, announced today that it has ... have an independent technology judge determine who has the ... tech/sophisticated telephone calling platform, and the best customer service. ... most of what we do – which clearly is ...
Breaking Biology News(10 mins):